Human Tissue Factor (TF) AssayMax™ELISA KitHuman Tissue Factor (TF) AssayMax™ELISA Kit
Move your mouse over image or click to enlarge

Human Tissue Factor (TF) AssayMax™ELISA Kit

This assay employs a quantitative enzyme immunoassay technique that measures the specified antigen in samples.

Cat# Size Price Qty Buy
ET1002-1 96 Well Plate £276.25

Additional Information

Property Value or Rating
Manufacturer Assaypro, LLC.
Product Type AssayMax™ ELISA Kits
Samples Serum, Cell Culture, Tissue Extract
Species Human
Reactivity Human
Assay Format Sandwich ELISA
Product Size 96 Well Plate
Range 12.5-400 pg/ml
Plex Number 1
Storage Refer to component labels for details
Entrez Gene 2152
Omim 134390
UniProt P13726
UniGene Hs.62192
Special Notes For Research Use Only, Not To Be Used For Diagnostic Purposes
References * Siddiqui FA et al. (2002) The presence and release of tissue factor from human platelets. Platelets 13(4):247-253 
* Jesmin S et al. (2004) Temporal changes in pulmonary expression of key procoagulant molecules in rabbits with endotoxin-induced acute lung injury: elevated expression levels of protease-activated receptors. Thromb Haemost. 92(5):966-979 
* Henriksson CE et al. (2005) Discrepancy between tissue factor activity and tissue factor expression in endotoxin-induced monocytes is associated with apoptosis and necrosis. Thromb Haemost. 94(6):1236-44 
* Roth GA et al. (2006) Infection with a periodontal pathogen induces procoagulant effects in human aortic endothelial cells. Journal of Thrombosis and Haemostasis 4(10):2256-2261 
* Sawa H et al. (2006) Elevation of plasma tissue factor levels in patients with severe acute pancreatitis. J. Gastroenterol. 41(6):575-581 
* Emekli-Alturfan E et al. (2007) The Relation between Plasma Tissue Factor and Oxidized LDL Levels in Acute Coronary Syndromes. Pathophysiol Haemost Thromb. 36(6):290-297 
* Han J et al. (2008) An anticoagulant serine protease from the wasp venom of Vespa magnifica. Toxicon 51(5):914-922 
* He WJ et al. (2008) Activated protein C ratio, plasma tissue factor activity and activated factor VII in Chinese patients with coronary heart disease. Eur J Med Res. 13:47-51 
* Jiang DJ et al. (2009) Asymmetric dimethylarginine induces tissue factor expression in monocytes via NF-kappaB-dependent pathway: Role in acute coronary syndromes. Atherosclerosis 205(2):554-560 
* Teng YC et al. (2009) Coagulation and fibrinolysis related cytokine imbalance in preeclampsia: the role of placental trophoblasts. J. Perinat. Med. 37:343-348 
* Andersson E et al. (2010) Tissue factor in predicted severe acute pancreatitis. World J Gastroenterol 16(48): 6128-6134 
* Munuswamy-Ramanujam G et al. (2010) Neuroserpin, a thrombolytic serine protease inhibitor (serpin), blocks transplant vasculopathy with associated modification of T-helper cell subsets. Thromb Haemost. 103(3):545-555 
* Strijbos MH et al. (2010) Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel. European Journal of Cancer 46:2027-2035 
* Teng Y et al. (2010) The relationship between plasma and placental tissue factor, and tissue factor pathway inhibitors in severe pre-eclampsia patients. Thrombosis Research 126(1):e41-e45 
* Watson T et al. (2010) Relationship of Indices of Inflammation and Thrombogenesis to Arrhythmia Burden in Paroxysmal Atrial Fibrillation. Chest. 137(4):869-876 
* Jiang WH et al. (2011) Regulatory role of RhoA/Rho kinase in the effect of fluvastatin on tumor necrosis factor-alpha induced expression of tissue factor. Afr. J. Pharm. Pharmacol. 5(12):1462-1466 
* Priya N et al. (2011) Characterization of a unique dihydropyrimidinone, ethyl 4-(4-heptanoyloxyphenyl)-6-methyl-3,4-dihydropyrimidin-2-one-5-carboxylate, as an effective antithrombotic agent in a rat experimental model. Journal of Pharmacy and Pharmacology 63(9):1175-1185 
* Santos M (2011) Contraindication of inflammation and traditional cardiovascular risk development of subclinical aterosclerosos. University of Lisbon, Ph.D. Thesis 
* Wang Y et al. (2011) Prediction of response to docetaxel therapy based on the presence of tmprssg2:erg fusion in circulating tumor cells. USPTO Patent Applicaton #: #20110166030 
* Xiong Y et al. (2011) Alternations of Maternal and Cord Plasma Hemostasis in Preeclampsia Before and After Delivery. Hypertens Pregnancy. 30(3):347-358 
* Fernandez-Cadenas I et al. (2012) IL1B and VWF variants are associated with fibrinolytic early recanalization in patients with ischemic stroke. Stroke. 43(10):2659-2665 
* Santos MJ (2012) Early Vascular Alterations in SLE and RA Patients--A Step towards Understanding the Associated Cardiovascular Risk. PLoS One. 7(9):e44668.doi: 10.1371/journal.pone.0044668 
* Zhu H et al. (2012) Activation of coagulation, anti-coagulation, fibrinolysis and the complement system in patients with urticaria. Asian Pac J Allergy Immunol 31:43-50 
* Kohno K et al. (2013) Therapeutic agent for inflammary diseases, containing adenosine N1-Oxide as an effective ingredient. Patent application: 20130165399 A1 
* Wang R et al. (2015) Simultaneous detection of peripheral mononuclear cell and plasma tissue factor expression for prevention and treatment of ischemic cardiocerebrovascular diseases. Int J Clin Exp Pathol 8(5):5674-5680 

" title="

* Siddiqui FA et al. (2002) The presence and release of tissue factor from human platelets. Platelets 13(4):247-253 
* Jesmin S et al. (2004) Temporal changes in pulmonary expression of key procoagulant molecules in rabbits with endotoxin-induced acute lung injury: elevated expression levels of protease-activated receptors. Thromb Haemost. 92(5):966-979 
* Henriksson CE et al. (2005) Discrepancy between tissue factor activity and tissue factor expression in endotoxin-induced monocytes is associated with apoptosis and necrosis. Thromb Haemost. 94(6):1236-44 
* Roth GA et al. (2006) Infection with a periodontal pathogen induces procoagulant effects in human aortic endothelial cells. Journal of Thrombosis and Haemostasis 4(10):2256-2261 
* Sawa H et al. (2006) Elevation of plasma tissue factor levels in patients with severe acute pancreatitis. J. Gastroenterol. 41(6):575-581 
* Emekli-Alturfan E et al. (2007) The Relation between Plasma Tissue Factor and Oxidized LDL Levels in Acute Coronary Syndromes. Pathophysiol Haemost Thromb. 36(6):290-297 
* Han J et al. (2008) An anticoagulant serine protease from the wasp venom of Vespa magnifica. Toxicon 51(5):914-922 
* He WJ et al. (2008) Activated protein C ratio, plasma tissue factor activity and activated factor VII in Chinese patients with coronary heart disease. Eur J Med Res. 13:47-51 
* Jiang DJ et al. (2009) Asymmetric dimethylarginine induces tissue factor expression in monocytes via NF-kappaB-dependent pathway: Role in acute coronary syndromes. Atherosclerosis 205(2):554-560 
* Teng YC et al. (2009) Coagulation and fibrinolysis related cytokine imbalance in preeclampsia: the role of placental trophoblasts. J. Perinat. Med. 37:343-348 
* Andersson E et al. (2010) Tissue factor in predicted severe acute pancreatitis. World J Gastroenterol 16(48): 6128-6134 
* Munuswamy-Ramanujam G et al. (2010) Neuroserpin, a thrombolytic serine protease inhibitor (serpin), blocks transplant vasculopathy with associated modification of T-helper cell subsets. Thromb Haemost. 103(3):545-555 
* Strijbos MH et al. (2010) Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel. European Journal of Cancer 46:2027-2035 
* Teng Y et al. (2010) The relationship between plasma and placental tissue factor, and tissue factor pathway inhibitors in severe pre-eclampsia patients. Thrombosis Research 126(1):e41-e45 
* Watson T et al. (2010) Relationship of Indices of Inflammation and Thrombogenesis to Arrhythmia Burden in Paroxysmal Atrial Fibrillation. Chest. 137(4):869-876 
* Jiang WH et al. (2011) Regulatory role of RhoA/Rho kinase in the effect of fluvastatin on tumor necrosis factor-alpha induced expression of tissue factor. Afr. J. Pharm. Pharmacol. 5(12):1462-1466 
* Priya N et al. (2011) Characterization of a unique dihydropyrimidinone, ethyl 4-(4-heptanoyloxyphenyl)-6-methyl-3,4-dihydropyrimidin-2-one-5-carboxylate, as an effective antithrombotic agent in a rat experimental model. Journal of Pharmacy and Pharmacology 63(9):1175-1185 
* Santos M (2011) Contraindication of inflammation and traditional cardiovascular risk development of subclinical aterosclerosos. University of Lisbon, Ph.D. Thesis 
* Wang Y et al. (2011) Prediction of response to docetaxel therapy based on the presence of tmprssg2:erg fusion in circulating tumor cells. USPTO Patent Applicaton #: #20110166030 
* Xiong Y et al. (2011) Alternations of Maternal and Cord Plasma Hemostasis in Preeclampsia Before and After Delivery. Hypertens Pregnancy. 30(3):347-358 
* Fernandez-Cadenas I et al. (2012) IL1B and VWF variants are associated with fibrinolytic early recanalization in patients with ischemic stroke. Stroke. 43(10):2659-2665 
* Santos MJ (2012) Early Vascular Alterations in SLE and RA Patients--A Step towards Understanding the Associated Cardiovascular Risk. PLoS One. 7(9):e44668.doi: 10.1371/journal.pone.0044668 
* Zhu H et al. (2012) Activation of coagulation, anti-coagulation, fibrinolysis and the complement system in patients with urticaria. Asian Pac J Allergy Immunol 31:43-50 
* Kohno K et al. (2013) Therapeutic agent for inflammary diseases, containing adenosine N1-Oxide as an effective ingredient. Patent application: 20130165399 A1 
* Wang R et al. (2015) Simultaneous detection of peripheral mononuclear cell and plasma tissue factor expression for prevention and treatment of ischemic cardiocerebrovascular diseases. Int J Clin Exp Pathol 8(5):5674-5680 

" target="_blank">

* Siddiqui FA et al. (2002) The presence and release of tissue factor from human platelets. Platelets 13(4):247-253 
* Jesmin S et al. (2004) Temporal changes in pulmonary expression of key procoagulant molecules in rabbits with endotoxin-induced acute lung injury: elevated expression levels of protease-activated receptors. Thromb Haemost. 92(5):966-979 
* Henriksson CE et al. (2005) Discrepancy between tissue factor activity and tissue factor expression in endotoxin-induced monocytes is associated with apoptosis and necrosis. Thromb Haemost. 94(6):1236-44 
* Roth GA et al. (2006) Infection with a periodontal pathogen induces procoagulant effects in human aortic endothelial cells. Journal of Thrombosis and Haemostasis 4(10):2256-2261 
* Sawa H et al. (2006) Elevation of plasma tissue factor levels in patients with severe acute pancreatitis. J. Gastroenterol. 41(6):575-581 
* Emekli-Alturfan E et al. (2007) The Relation between Plasma Tissue Factor and Oxidized LDL Levels in Acute Coronary Syndromes. Pathophysiol Haemost Thromb. 36(6):290-297 
* Han J et al. (2008) An anticoagulant serine protease from the wasp venom of Vespa magnifica. Toxicon 51(5):914-922 
* He WJ et al. (2008) Activated protein C ratio, plasma tissue factor activity and activated factor VII in Chinese patients with coronary heart disease. Eur J Med Res. 13:47-51 
* Jiang DJ et al. (2009) Asymmetric dimethylarginine induces tissue factor expression in monocytes via NF-kappaB-dependent pathway: Role in acute coronary syndromes. Atherosclerosis 205(2):554-560 
* Teng YC et al. (2009) Coagulation and fibrinolysis related cytokine imbalance in preeclampsia: the role of placental trophoblasts. J. Perinat. Med. 37:343-348 
* Andersson E et al. (2010) Tissue factor in predicted severe acute pancreatitis. World J Gastroenterol 16(48): 6128-6134 
* Munuswamy-Ramanujam G et al. (2010) Neuroserpin, a thrombolytic serine protease inhibitor (serpin), blocks transplant vasculopathy with associated modification of T-helper cell subsets. Thromb Haemost. 103(3):545-555 
* Strijbos MH et al. (2010) Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel. European Journal of Cancer 46:2027-2035 
* Teng Y et al. (2010) The relationship between plasma and placental tissue factor, and tissue factor pathway inhibitors in severe pre-eclampsia patients. Thrombosis Research 126(1):e41-e45 
* Watson T et al. (2010) Relationship of Indices of Inflammation and Thrombogenesis to Arrhythmia Burden in Paroxysmal Atrial Fibrillation. Chest. 137(4):869-876 
* Jiang WH et al. (2011) Regulatory role of RhoA/Rho kinase in the effect of fluvastatin on tumor necrosis factor-alpha induced expression of tissue factor. Afr. J. Pharm. Pharmacol. 5(12):1462-1466 
* Priya N et al. (2011) Characterization of a unique dihydropyrimidinone, ethyl 4-(4-heptanoyloxyphenyl)-6-methyl-3,4-dihydropyrimidin-2-one-5-carboxylate, as an effective antithrombotic agent in a rat experimental model. Journal of Pharmacy and Pharmacology 63(9):1175-1185 
* Santos M (2011) Contraindication of inflammation and traditional cardiovascular risk development of subclinical aterosclerosos. University of Lisbon, Ph.D. Thesis 
* Wang Y et al. (2011) Prediction of response to docetaxel therapy based on the presence of tmprssg2:erg fusion in circulating tumor cells. USPTO Patent Applicaton #: #20110166030 
* Xiong Y et al. (2011) Alternations of Maternal and Cord Plasma Hemostasis in Preeclampsia Before and After Delivery. Hypertens Pregnancy. 30(3):347-358 
* Fernandez-Cadenas I et al. (2012) IL1B and VWF variants are associated with fibrinolytic early recanalization in patients with ischemic stroke. Stroke. 43(10):2659-2665 
* Santos MJ (2012) Early Vascular Alterations in SLE and RA Patients--A Step towards Understanding the Associated Cardiovascular Risk. PLoS One. 7(9):e44668.doi: 10.1371/journal.pone.0044668 
* Zhu H et al. (2012) Activation of coagulation, anti-coagulation, fibrinolysis and the complement system in patients with urticaria. Asian Pac J Allergy Immunol 31:43-50 
* Kohno K et al. (2013) Therapeutic agent for inflammary diseases, containing adenosine N1-Oxide as an effective ingredient. Patent application: 20130165399 A1 
* Wang R et al. (2015) Simultaneous detection of peripheral mononuclear cell and plasma tissue factor expression for prevention and treatment of ischemic cardiocerebrovascular diseases. Int J Clin Exp Pathol 8(5):5674-5680 

Related Documents